if you guys google replicel you will see that they have gotten some very promising results from their research.
basicaly they pull out these cells from the back of you head called dermal sheath cup cells. they then proliferate them in a petri dish and deposit them under you skin in the scalp.
they just completed one clinical trial and are due to start the next this year. however it will probably be a few years until it gets made public.
Sun Apr 29, 2012 11:35pm EDT
VANCOUVER, BRITISH COLUMBIA, Apr 29 (MARKET WIRE) --
RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB:REPCF)
wishes to clarify statements made in its April 27, 2012 news release.
Specifically, comments made by NBT Equities Research LLC analyst Tobin
Smith, concerning price targets and statements made in his report which
were published in newsletters available online or delivered via email
newsletter, including by TheHotPennyStocks.com, hotstocked.com, StockGuru
and in other disclosures, were the thoughts and views of Tobin Smith,
however were paid for and authorized by the Company. The Company wishes
to make a general retraction in respect of these disclosures.
Specifically, the Company wishes to make clear that, given the Company's
current stage of development, price targets and estimates pertaining to
expected increases in the Company's share price, as published in the
aforementioned reports are premature and cannot be relied upon. Price
targets and dramatic increases in share prices indicated in such
publications may never be met and there are many risks and uncertainties
pertaining to the Company's business and shares that
may cause investors
to lose their entire investment in the Company, including that the
Company's technology may not work as expected and, even if it does work
as expected, the Company may be unable to successfully commercialize the
technology or protect its intellectual property from competitors. Other
risks and uncertainties pertaining to the Company's business are set out
in the Company's annual report, which is filed on Sedar (
www.sedar.com)
and Edgar (
www.sec.gov).
Contacts:
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
604-248-8696
tg@replicel.com
www.replicel.com